drug · antibody
Tevimbra
Phase 3updated 6mo agoby $ONC BeOne Medicines Ltd.🔗 ChEMBL
Phase 3community read0 votes
🐶 often sniffed alongside
top 1Antibody drug with a maximum clinical stage of Approval (across all indications), with 7 approved and 50 investigational indications.
indications
indications
NSCLC
targets
Programmed cell death protein 1
all catalysts(0)
nothing on the calendar yet
News(10)
- China has a clear shot to 2030 goals, though economic, cultural barriers remainTo grow into a biopharma juggernaut, China aims to become the leading source of innovative medicines on the global markets—a goal that experts say the country is on track to hit.biospace · 6d ago
- 6 potential blockbusters that could pave China’s path to 2030 ambitionsIn its latest five-year plan, China has set its sights on developing five drugs that could each rake in more than $1 billion globally by 2030. Experts say it's well on its way, with two medications…biospace · 13d ago
- 5 biggest venture capital raises of Q3 2026Venture capital continued to flow into biopharma in the third quarter, though experts pointed out that investors remained selective, preferring to put their money behind advanced and derisked asset…biospace · 1mo ago
- Solstice rises with $225M to develop next-gen CTLA-4 drug from ChinaSolstice Oncology, founded in February, is emerging from stealth having already secured an investigational new drug application from the FDA for a Phase 2 trial of a CTLA-4 antibody purchased from…biospace · 2mo ago
- Mid-cap biotechs join Trump’s latest round of drug pricing dealsFocused on Medicaid, the new pacts now involve more than just large pharmaceutical companies, but still aren’t expected to meaningfully impact drugmaker profits.biopharma_dive · 2mo ago
- Jazz scores front-line gastric cancer nod from FDA for ‘practice-changing’ ZiiheraGastroesophageal adenocarcinoma presents the biggest market opportunity for Jazz Pharmaceuticals’ Ziihera, according to Truist Securities, which forecasts peak sales of the drug to reach $2.5 billion.biospace · 2mo ago
- New Jazz cancer drug approval could drive blockbuster salesZiihera can now be used as an initial treatment for all HER2-positive gastroesophageal adenocarcinomas, dramatically expanding the drug’s market potential.biopharma_dive · 2mo ago
- Summit, Merck must navigate new regulatory terrain in China-first cancer landscapeSummit Therapeutics revealed positive Western data last week from a Phase 3 trial of lung cancer candidate ivonescimab. In a flipped geographical clinical trials landscape, what more will be requir…biospace · 3mo ago
- Akeso, Summit drug extends survival in closely watched lung cancer trialThough ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study, the total survival benefit of four months stirred debate and pressured company shares.biopharma_dive · 5mo ago
- OncLive Polls Reveal Picks for Top Lung Cancer Abstracts at ASCO 2026Lung cancer experts rank key abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.onclive · 6mo ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that